Aurobindo Pharma reported a consolidated net profit of ₹1,032 crore for Q1FY27, a 25.2% increase from ₹824 crore in the same period last year. Revenue from operations grew 16.3% year-on-year to ₹9,150 crore, driven by robust volume gains in Europe and the US, alongside new product launches. The company maintained an operating EBITDA margin of 21.0%, expanding by 60 basis points compared to Q1FY26, while generating free cash flow of US$ 98 million despite significant capital deployment for acquisitions and buybacks.

The unaudited financial results for the quarter ended June 30, 2026, were submitted to the National Stock Exchange of India Limited and BSE Limited on August 5, 2026, under Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. B. Adi Reddy, Company Secretary, signed the disclosure. An investor and analyst call was scheduled for August 6, 2026, to discuss the performance.

Financial Performance

Revenue growth was broad-based across geographies. US formulations revenue rose 8.1% year-on-year to ₹3,770 crore (US$ 399 million), supported by volume gains and ten new product launches. Europe saw a sharper 25.6% increase to ₹2,937 crore (EUR 267 million), accounting for 32.1% of consolidated revenue. Growth markets expanded by 37.7% to ₹1,063 crore (US$ 113 million). The API segment contributed ₹1,049 crore, up 14.6% year-on-year, though it faced sequential softness due to seasonal factors in antibiotics. ARV revenue remained stable at ₹330 crore.

*Operating EBITDA excludes a one-time expense of ₹43 crore related to the derecognition of lease receivables.

Cash Flow and Capital Allocation

Despite heavy capital deployment, Aurobindo Pharma generated free cash flow from business of US$ 98 million in Q1FY27. This was achieved after accounting for normal capex of US$ 40 million. The company utilized cash for the Lannett acquisition (US$ 247 million), share buybacks (US$ 85 million), and new business development capex (US$ 20 million). As of June 30, 2026, the company held a net cash position (including investments) of approximately US$ 42 million. Gross debt stood at US$ 887 million, comprising working capital loans of US$ 800 million and other term loans of US$ 87 million.

What the Numbers Show

The divergence between operating EBITDA growth (20.0%) and net profit growth (25.2%) highlights the impact of non-operating items. While operating margins expanded modestly, the bottom line benefited significantly from other income, which nearly doubled to ₹212 crore from ₹105 crore in Q1FY26, alongside a foreign exchange gain of ₹53 crore. Conversely, the one-time lease derecognition expense of ₹43 crore tempered reported EBITDA figures, though operational profitability remained robust across all key segments. Basic and diluted EPS stood at ₹17.86 per share.

Biosimilars and Contract Manufacturing Updates

CuraTeQ Biologics advanced its regulatory and commercial footprint. The company secured ANVISA GMP certification for Brazil and filed Denosumab biosimilars (FILVIZY and FUGEVY) with the EMA. Commercially, all four MHRA-approved products are now supplying in the UK, with multi-country rollouts underway in Europe and initial entries into Mexico and Algeria. TheraNym, the biologics contract manufacturing arm, inaugurated Unit 1 on June 3, 2026, with qualification activities set for November 2026. Construction on Unit 2, estimated at US$ 180 million, is scheduled to begin in October 2026.

Aurobindo Pharma Limited has disclosed the web-link to its Integrated Annual Report for the financial year ended March 31, 2026 (FY26), pursuant to Regulation 36(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This disclosure precedes the company’s 39th Annual General Meeting (AGM) scheduled for Thursday, August 27, 2026, where shareholders will approve the audited financial statements and confirm an interim dividend of ₹4 per equity share.

The company notified the National Stock Exchange of India Limited and BSE Limited on August 4, 2026, that physical copies of the Annual Report have been sent only to members who have not registered email addresses with the company or depositories. For all other shareholders, the report is accessible via the company’s website or through a dedicated QR code. The disclosure ensures compliance with regulatory mandates for timely dissemination of financial information.

Key Disclosures and Shareholder Actions

Shareholders are advised to access the Integrated Annual Report 2025-26 through the following channels:

In addition to accessing the report, shareholders are urged to update their Know Your Customer (KYC) details, including PAN, postal address with pin code, email address, mobile number, bank account details, and nomination details. The Registrar and Transfer Agent (RTA), KFin Technologies Limited, has mandated that any payments, including dividends, for folios with incomplete KYC or PAN details will be made electronically only upon registration of the required information.

AGM and E-Voting Schedule

The 39th AGM will be conducted exclusively via Video Conferencing (VC) or Other Audio Visual Means (OAVM). The key dates for shareholder participation are as follows:

The Register of Members and Share Transfer Books will remain closed from August 26 to August 27, 2026. Institutional investors must submit board resolutions authorizing representatives to vote via email to the scrutinizer, M/s. RPR & Associates.

Governance and Auditor Updates

The AGM agenda includes the reappointment of Mr. K. Nithyananda Reddy and Dr. M. Madan Mohan Reddy, who retire by rotation. Additionally, the Board has recommended the appointment of M/s. RPR & Associates as the Secretarial Auditor for a term of five years, from FY27 to FY31, replacing M/s. MRR & Associates which resigned on May 21, 2026. This appointment aligns with Regulation 24A of the SEBI Listing Regulations and Section 204 of the Companies Act, 2013.

What the Numbers Show

The proactive disclosure of the Annual Report web-link underscores Aurobindo Pharma’s adherence to digital transparency norms under SEBI regulations. The emphasis on updating KYC details highlights a broader industry shift towards electronic dividend payments, reducing reliance on physical instruments. For shareholders, ensuring updated records is critical to receiving the confirmed ₹4 per share interim dividend without delay.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE406A01037/b3cb4f5b-80cd-4b19-b8df-63e744f70c28.pdf